<DOC>
	<DOCNO>NCT00670397</DOCNO>
	<brief_summary>RATIONALE : Photodynamic therapy use drug , HPPH , absorb tumor cell . The drug become active expose light . When drug active , tumor cell kill . PURPOSE : This phase I trial study side effect best dose photodynamic therapy use HPPH treat patient recurrent dysplasia , carcinoma situ , stage I oral cavity cancer .</brief_summary>
	<brief_title>Photodynamic Therapy Using HPPH Treating Patients With Recurrent Dysplasia , Carcinoma Situ , Stage I Oral Cavity Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine maximum tolerate dose oral cavity photodynamic therapy ( PDT ) use HPPH 665 nm light patient recurrent dysplasia , carcinoma situ , stage I squamous cell carcinoma oral cavity . Secondary - To determine response dysplasia , carcinoma situ , select patient T1 squamous cell carcinoma oral cavity use PDT HPPH 665 nm light . OUTLINE : This dose-escalation study laser light dose therapy . Patients receive HPPH IV 1 hour day 1 . Approximately 24 hour receive HPPH , patient undergo laser light treatment tumor bed day 2 . Patients multicentric large area confluent disease receive second course treatment least 8 week later lesion untreated first treatment session . After completion study treatment , patient follow 1 week , 1 month , 3 month , periodically thereafter .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Mouth Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Biopsyconfirmed diagnosis 1 following : Mild severe dysplasia Carcinoma situ ( CIS ) oral cavity Carcinoma must less 3mm thick Stage I ( T1 ) squamous cell carcinoma oral cavity Recurrent primary disease No T2 great squamous cell carcinoma , exophytic CIS , dysplasia lesion PATIENT CHARACTERISTICS : ECOG performance status 02 Total bilirubin ≤ 2.0 mg/dL Creatinine ≤ 2.0 mg/dL Alkaline phosphatase ≤ 3 time upper limit normal ( ULN ) SGOT ≤ 3 time ULN Not pregnant Fertile patient must use effective contraception No porphyria hypersensitivity porphyrin porphyrinlike compound PRIOR CONCURRENT THERAPY : Prior therapy type allow More 4 week since prior concurrent chemotherapy radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>stage I squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage 0 lip oral cavity cancer</keyword>
</DOC>